Abstract: The invention provides a method of making a peptide or peptide derivative comprising the amino acid sequence comprising imfwydcye or a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye.
Abstract: The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.
Type:
Grant
Filed:
October 27, 2009
Date of Patent:
March 7, 2017
Assignees:
BAXALTA GMBH, BAXALTA INCORPORATED
Inventors:
Hans-Peter Schwarz, Eva-Maria Muchitsch, Peter Turecek
Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
Type:
Grant
Filed:
May 3, 2016
Date of Patent:
February 21, 2017
Assignees:
BAXALTA INCORPORATED, BAXALTA GMBH
Inventors:
Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
Type:
Grant
Filed:
April 2, 2015
Date of Patent:
January 31, 2017
Assignees:
BAXALTA GMBH, BAXALTA INCORPORATED
Inventors:
Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
Abstract: The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), are also provided.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
January 31, 2017
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Lucia Gnauer, Harald Arno Butterweck, Theresa Bauer, Alfred Weber, Wolfgang Teschner, Hans-Peter Schwarz
Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
Type:
Grant
Filed:
February 25, 2014
Date of Patent:
January 31, 2017
Assignees:
Baxalta Incorporated, Balxalta GmbH
Inventors:
William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.
Type:
Grant
Filed:
September 13, 2013
Date of Patent:
January 17, 2017
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
Abstract: The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor VII (rFVIIa), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rFVIIa.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
January 17, 2017
Assignees:
BAXALTA GMBH, BAXALTA INCORPORATED
Inventors:
Ernst Böhm, Michael Dockal, Andrea Sedivy
Abstract: A method of mixing a fluid includes positioning a flexible bag into the chamber of a support housing, the support housing having a plurality of baffles positioned so that the bag folds around the baffles. A fluid is delivered into a compartment of the flexible bag. A mixing element, such as an impeller, is moved within the compartment of the flexible bag so as to mix the fluid therein.
Type:
Grant
Filed:
December 17, 2013
Date of Patent:
January 10, 2017
Assignees:
Life Technologies Corporation, Baxalta Incorporated, Baxalta GmbH
Inventors:
Kurt T. Kunas, Robert V. Oakley, Fauad F. Hasan, Michael E. Goodwin, Jeremy K. Larsen, Nephi D. Jones
Abstract: Embodiments disclosed herein provide systems and methods that increase protein yield from recombinant manufacturing processes. The systems and methods treat used depth filters with bound proteins of interest as a stationary phase exchange resin to recapture bound protein of interest from the depth filter.
Abstract: Methods of preparing alpha-1-antiproteinase inhibitor and controlling the amount of des-lys alpha-1-antiproteinase inhibitor in the preparation, and compositions comprising the same, as well as methods of treatment using the same are provided.
Type:
Grant
Filed:
May 27, 2014
Date of Patent:
December 6, 2016
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Peter Matthiessen, Alfred Weber, Peter Turecek, Hans-Peter Schwarz
Abstract: The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
Type:
Grant
Filed:
January 23, 2015
Date of Patent:
December 6, 2016
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Katharina Nora Steinitz, Paula Maria Wilhelmina van Helden, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich
Abstract: The present invention provides compositions and pharmaceutical formulations of IaIp derived from plasma. Also provided are methods for the manufacture of the IaIp compositions and formulations, as well as method for the treatment of diseases associated with IaIp dysfunction.
Type:
Grant
Filed:
August 19, 2014
Date of Patent:
November 29, 2016
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Shawn F. Bairstow, Jennifer Hutsell, Sindhu Ramachandran
Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.
Inventors:
Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
Type:
Grant
Filed:
December 20, 2013
Date of Patent:
November 15, 2016
Assignees:
BAXALTA INCORPORATED, BAXALTA GMBH
Inventors:
Stefan Haider, Andreas Ivens, Hanspeter Rottensteiner, Juergen Siekmann, Peter Turecek
Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
Type:
Grant
Filed:
November 20, 2014
Date of Patent:
November 8, 2016
Assignees:
BAXALTA INCORPORATED, BAXALTA GMBH
Inventors:
Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
Type:
Grant
Filed:
June 4, 2014
Date of Patent:
October 18, 2016
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
Abstract: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.
Type:
Grant
Filed:
January 30, 2012
Date of Patent:
October 11, 2016
Assignees:
BAXALTA INCORPORATED, BAXALTA GMBH
Inventors:
Falko-Günter Falkner, Birgit Schafer, P. Noel Barrett, Thomas R. Kreil, Hartmut Ehrlich, Annett Hessel
Abstract: The present invention is concerned with the specific and highly sensitive detection of specific CHO-MIF (macrophage migration inhibitory factor from Chinese Ovarian Hamster cell line) complexes in the production of anti-MIF antibodies. The present invention is further concerned with the provision of specific antibodies which can be used for a CHO-MIF detection method. The present invention is also concerned with a CHO MIF knockout cell line and use thereof. The present invention also provides preparations obtained from recombinant production in CHO cell lines which are essentially free of CHO-MIF.
Type:
Grant
Filed:
October 4, 2012
Date of Patent:
October 11, 2016
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Randolf J. Kerschbaumer, Dirk Voelkel, Gerhard Antoine, Friedrich Scheiflinger, Geert C. Mudde